Chemotherapy-induced peripheral neuropathy using Pain Vision Observational Study to Investigate the Effectiveness of Objective Evaluation

Chemotherapy-induced peripheral neuropathy using Pain Vision Observational Study to Investigate the Effectiveness of Objective Evaluation - Chemotherapy-induced peripheral neuropathy using Pain Vision Observational Study to Investigate the Effectiveness of Objective Evaluation

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000052769

Enrollment

180

Registered

2023-11-12

Start date

2023-11-12

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients who developed peripheral neuropathy during chemotherapy treatment at our hospital and were evaluated as NCI-CTCEA Grade 2 by the pharmacist

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients 18 years of age or older who have been evaluated as Grade 2 or higher by the chemotherapy room pharmacist between the date of approval and December 31, 2028. Patients who have given written consent to participate in this study

Exclusion criteria

Exclusion criteria: Patients being treated with implantable medical devices such as pacemakers and ICDs Other patients who are judged to be inappropriate by the doctor's judgment

Design outcomes

Primary

Measure	Time frame
[Main evaluation items] Patient VAS and questionnaire method FACT/GOG-Ntx (Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity), PNQ (Patient Neurotoxicity Questionnaire) and Pain vision (pain frequency, lowest perceived current value, pain perceived current value ) [Secondary evaluation items] participation rate Effectiveness of supportive care (duloxetine, gabapentinoids, opioids)	—

Measure

Time frame

[Main evaluation items] Patient VAS and questionnaire method FACT/GOG-Ntx (Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity), PNQ (Patient Neurotoxicity Questionnaire) and Pain vision (pain frequency, lowest perceived current value, pain perceived current value ) [Secondary evaluation items] participation rate Effectiveness of supportive care (duloxetine, gabapentinoids, opioids)

—

Countries

Japan

Contacts

Public ContactYoshmi Nakamura

Gifu University Hospital Department of Anesthesiology and Pain Medicine

nakamura.yoshimi.f7@f.gifu-u.ac.jp0582306404

Outcome results